Eli Lilly and vs UnitedHealth Group: Business Model & Financial Comparison 2026
Eli Lilly and · Healthcare / Drug Manufacturers - General·UnitedHealth Group · Healthcare / Healthcare Plans
Financial Comparison
| Metric | LLYEli Lilly and | UNHUnitedHealth Group |
|---|---|---|
| Market Cap | $893.59B | $255.56B |
| Revenue (TTM) | $65.18B | $447.57B |
| Revenue Growth | 42.6% | 12.3% |
| Gross Margin | 83.0% | 18.5% |
| Operating Margin | 44.9% | 0.3% |
| Net Margin | 31.7% | 2.7% |
| Return on Equity | 101.2% | 12.5% |
| P/E (Trailing) | 43.5x | 21.3x |
| P/E (Forward) | 23.8x | 14.1x |
| Free Cash Flow | $1.95B | $13.86B |
| Cash | $7.27B | $28.12B |
| Total Debt | $43.87B | $83.00B |
Data sourced from Yahoo Finance. Green highlights indicate better performance for that metric. Use the interactive tool for real-time data.
Business Model Comparison
Eli Lilly and
Eli Lilly and Company stands as a leading company in Healthcare. Generating $65.18 billion in annual revenue (growing 42.6% year-over-year) and carrying a market capitalization of $880.04 billion, the company has cemented its position as a foundational player in the global Drug Manufacturers - General landscape. Under the leadership of its leadership team, Eli Lilly and Company continues to execute on a multi-year strategic vision that balances g…
Full Eli Lilly and analysis →UnitedHealth Group
UnitedHealth Group Incorporated stands as a leading company in Healthcare. Generating $447.57 billion in annual revenue (growing 12.3% year-over-year) and carrying a market capitalization of $261.58 billion, the company has cemented its position as a foundational player in the global Healthcare Plans landscape. Under the leadership of its leadership team, UnitedHealth Group Incorporated continues to execute on a multi-year strategic vision that b…
Full UnitedHealth Group analysis →SWOT Analysis Comparison
Strengths
Eli Lilly and
- With a market capitalization of $880.04B, Eli Lilly and Company is one of the largest companies in its sector, providing the scale advantages of brand recognition, supplier leverage, and capital acces
- Eli Lilly and Company's gross margin of 83.0% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of 44.9% demonstrates
- Revenue grew 42.6% year-over-year to $65.18B, indicating strong demand for Eli Lilly and Company's products and services and outperformance relative to many industry peers.
UnitedHealth Group
- With a market capitalization of $261.58B, UnitedHealth Group Incorporated is one of the largest companies in its sector, providing the scale advantages of brand recognition, supplier leverage, and cap
- Revenue grew 12.3% year-over-year to $447.57B, indicating strong demand for UnitedHealth Group Incorporated's products and services and outperformance relative to many industry peers.
- UnitedHealth Group Incorporated generated $13.86B in free cash flow, providing financial flexibility to invest in growth initiatives, return capital to shareholders, or strengthen the balance sheet.
Weaknesses
Eli Lilly and
- With a debt-to-equity ratio of 165.3, Eli Lilly and Company carries significant debt relative to equity. While manageable given its cash flow, elevated leverage limits financial flexibility and increa
UnitedHealth Group
- UnitedHealth Group Incorporated's debt-to-equity ratio of 81.6 indicates meaningful financial leverage. Total debt stands at $83.00B against $28.12B in cash and equivalents.
- A net profit margin of 2.7% leaves limited buffer against revenue fluctuations or cost increases. Any significant market downturn could quickly pressure profitability.
- With 390,000 employees globally, UnitedHealth Group Incorporated faces inherent challenges in agility, decision-making speed, and maintaining a consistent culture across geographies — advantages that
Opportunities
Eli Lilly and
- Eli Lilly and Company operates in the Drug Manufacturers - General segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains i
- Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Eli Lil
- Earnings growth of 51.4% YoY demonstrates Eli Lilly and Company's ability to convert revenue growth into shareholder value. Analysts project continued earnings expansion driven by operating leverage a
UnitedHealth Group
- UnitedHealth Group Incorporated operates in the Healthcare Plans segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in
- Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for UnitedH
- With $28.12B in cash and strong free cash flow generation, UnitedHealth Group Incorporated is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographi
Threats
Eli Lilly and
- Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Eli Lilly and Company's revenue is not fully insulated from macroeconomic cycles, and a rece
- Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Eli Lilly and Compa
- Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri
UnitedHealth Group
- Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. UnitedHealth Group Incorporated's revenue is not fully insulated from macroeconomic cycles,
- Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on UnitedHealth Group
- Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri
Compare any 2–4 companies with live data
The interactive comparison tool lets you select any companies, see real-time metrics, and export a side-by-side report.
Open Comparison ToolEli Lilly and vs UnitedHealth Group: FAQ
- Is Eli Lilly and bigger than UnitedHealth Group?
- By market capitalization, Eli Lilly and is larger at $893.59B vs UnitedHealth Group's $255.56B.
- Which has better profit margins — Eli Lilly and or UnitedHealth Group?
- Eli Lilly and has higher net profit margins (31.7%) compared to UnitedHealth Group (2.7%). Gross and operating margins are compared in the table above.
- What sectors do Eli Lilly and and UnitedHealth Group operate in?
- Eli Lilly and operates in the Healthcare sector (Drug Manufacturers - General). UnitedHealth Group operates in the Healthcare sector (Healthcare Plans).
- How does Eli Lilly and's revenue compare to UnitedHealth Group's?
- Eli Lilly and generates $65.18B in annual revenue (TTM) while UnitedHealth Group generates $447.57B. UnitedHealth Group is the larger company by revenue as of 2026.